Kornimate/medical-research-clean huggingface dataset:
left lateral position and supine position in eus-ppg measurement

Conditions: Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS); Varices, Esophageal; Gastric Varices

Summary: the consistency of eus-ppg measurements between left lateral decubitus and supine positions is unclear. in this rospective comparative study, we are aimed to evaluate the correlation between eus-ppg measured in supine position (eus-suppg), and eus-ppg measured in left lateral decubitus position (eus-leppg).

the hepatic venous pressure gradient (hvpg) remains the gold standard for assessing portal hypertension, yet its clinical application faces several limitations. first, hvpg has restricted diagnostic scope, being unable to accurately evaluate prehepatic or presinusoidal portal hypertension. second, the measurement process exposes both patients and physicians to radiation and involves complex techniques that preclude routine implementation in many hospitals. finally, as hvpg indirectly estimates portal pressure through wedged hepatic venous pressure, its accuracy may be compromised by multiple factors including intrahepatic venous shunting, catheter insertion depth, excessive sedation or patient agitation during the procedure, and incomplete balloon occlusion of hepatic venous flow. endoscopic ultrasound-guided portal pressure gradient (eus-ppg) measurement effectively addresses these limitations of hvpg. current clinical studies on eus-ppg have predominantly been conducted in the supine position. however, this position significantly increases the technical difficulty of endoscopic ultrasonography and complicates the simultaneous performance of endoscopic selective varices devascularization (eus-esvd) under single anesthesia. the consistency of eus-ppg measurements between left lateral decubitus and supine positions requires further investigation. this prospective comparative study enrolls hospitalized patients with liver cirrhosis complicated by esophagogastric varices. prior to endoscopic treatment, we perform eus-guided puncture of both the portal vein and hepatic vein using a 25g needle. pressure transducers measure the portal venous pressure (pvp) and hepatic venous pressure (hvp), with their differential defined as eus-ppg. measurements obtained in supine position are designated eus-suppg, while those in left lateral decubitus position are termed eus-leppg. statistical analysis will evaluate the correlation between eus-suppg and eus-leppg values, with postoperative monitoring for complications including infection and hemorrhage.

Eligibility criteria:
inclusion criteria: * the gastroesophageal variceal patients hospitalized for endoscopic therapy, and are willing to sign the informed consent of measuring portal vein pressure gradient under endocsopic ultrasound. exclusion criteria: * （1）unwilling to sign the informed consent （2）uncorrectable coagulopathy (inr\>1.5) （3）uncorrectable thrombocytopenia (platelets \<20,000/μl) （4）bacteremia （5）age\<18,or≥81 （6）pregnancy
study using wst11 in patients with non-resectable or inoperable cholangiocarcinoma

Conditions: Cholangiocarcinoma

Summary: the aim of this study is to evaluate the safety of vascular targeted photodynamic therapy with wst11 in patients with non-resectable or inoperable biliary carcinoma.

this is an open-label, prospective, multicentre, phase iia study, evaluating a new therapeutic agent in the management of patients suffering from inoperable or non resectable biliary carcinoma. the patients will receive the dose of wst11 according to order of inclusion. the first 3 patients will receive 2.5 mg/kg. in the absence of toxicity, the following 9 patients will receive the dose of 5 mg/kg. the patient is to receive anesthesia. wst11-mediated therapy will consist of the combination of single iv administration of wst11 at doses of 2.5mg/kg or 5mg/kg, using 753nm laser light at a fixed power of (150mw/cm) and light energy (200 j/cm) delivered through a diffusing fiber. the fiber is introduced in a transparent standard ercp catheter and positioned under radioscopy in front of the lesion.

Eligibility criteria:
inclusion criteria: * patient having signed the consent form to take part in the study * patient aged over 18 years, with no upper age limit * patient with histologically proven cholangiocarcinoma * patient with cholangiocarcinoma, inoperable or non resectable owing to extension, age or concomitant diseases * bilirubin level decrease of more than 50% after stent insertion compared to base level * patient with a who performance scale ≤ 2 * patient in whom efficient drainage is performed by means of a plastic biliary stent endoscopically or radiologically * patient capable of completing the quality of life questionnaires * women of child-bearing potential must have a negative pregnancy test, and must thereafter prove to be using acceptable contraception (oral contraceptive pill, hormone patches, or iud) exclusion criteria: * absence of consent to take part in the study * patient with operable biliary carcinoma * class asa iv patients * patients presenting clinical and laboratory signs of biliary infection * absence of bilirubin decrease after stent insertion * patients with extrinsic biliary compression * patients already having received or currently receiving radiotherapy or chemotherapy for cholangiocarcinoma or needing to be treated during the first month of the follow-up * known metastatic lesions * patients having received immediate treatment by insertion of a metal stent * patients with porphyria or known hypersensitivity to porphyrins (contraindication to wst11) * patient receiving prohibited treatment at the time of inclusion in the study * pregnant or breast-feeding women * non-menopausal women not using effective contraception * majors under protection as per the french public health code * persons not registered with or covered by a social security system * persons in an exclusion period relative to other biomedical study

Keywords: inoperable inoperable cholangiocarcinoma non-resectable non-resectable cholangiocarcinoma carcinoma
implantable cardioverter defibrillators and magnetic resonance imaging of the heart at 1.5 tesla

Conditions: Defibrillators, Implantable; Heart Failure, Congestive

Summary: to evaluate short-term and long-term effects by mr imaging on the technical and functional status of implantable cardioverter defibrillators.

the presence of an implantable cardioverter defibrillators (icd) is currently considered an absolute contraindication to mr imaging, and most patients with pm are excluded from having mri. as a result from studies such as madit i, madit ii, scdheft etc. the number of patients with icds has been continuously growing over the past years, ans this development will continue. the aim of this study is to develop a strategy for safe performance of mr imaging at 1.5t, which included restriction of specific absorption rate (sar) values to minimize the risk of lead heating, and icd reprogramming to avoid interference from time varying gradient fields. the safety of this approach is then evaluated in a large group of icd patients including assessment of potential myocardial thermal injury by measuring serum troponin i and pacing capture thresholds, and performing a follow-up 6 weeks after mr imaging to evaluate long-term effects.

Eligibility criteria:
inclusion criteria: * implantable cardioverter defibrillator * congestive heart failure * informed consent exclusion criteria: * non-mri-compatible implants

Keywords: defibrillators, implantable heart failure, congestive magnetic resonance imaging
to demonstrate the relative bioavailability of bupropion hci 300 mg extended-release tablets under fasting conditions

Conditions: Depression

Summary: the purpose of this study is to demonstrate the relative bioequivalence of bupropion hci 300 mg er tablets under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b orc. * treatment for drug or alcohol dependence.
effect of endostar combined with chemotherapy and radiotherapy on blood vessels and microenvironment of tumor for non-small cell lung cancer (nsclc)

Conditions: Non-small Cell Lung Cancer

Summary: primary objective: functional imaging and quantitative imaging detection of the effects of endostar combined with chemotherapy and radiotherapy on non-small cell lung cancer (nsclc). secondary objective: to evaluate 1) the role of endostar in regulating tumor vessels and normalizing of microenvironment; 2) toxicity of endostar combined with chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven inoperable stage iiib-iv nsclc * ecog ps 0-1 * life expectancy \> 3 months * adequate blood functions: absolute neutrophil count (anc) ≥ 1.5 x 109/l, platelet count ≥ 100 x 109/l, and hemoglobin ≥ 9 g / dl * adequate liver function: total bilirubin \<1.5 times the upper limit of normal (uln); ast and alt \<2.5 times uln in patients without liver metastases, \<5 times uln in patients with liver metastases * adequate renal function: serum creatinine ≤ 1.25 times uln or calculated creatinine clearance ≥ 50 ml / min and urinary protein \<2+. in patients with baseline urinary protein ≥ 2+, 24 hours urine should be collected and 24 hours urine protein ≤ 1g * international normalized ratio (inr) ≤ 1.5 and prothrombin time(pt) ≤ 1.5 times uln within 7 days before enrollment * written informed consent exclusion criteria: * evidence of bleeding diathesis or coagulopathy * history of hemoptysis, defined as bright red blood more than half a teaspoon 3 months before enrollment * previously received chemotherapy and radiotherapy and biological targeted therapy * uncontrolled hypertension (systolic blood pressure\> 150 mmhg and/or diastolic blood pressure\> 100 mm hg) * clinically significant (ie, active) cardiovascular diseases, such as cerebrovascular accident (within 6 months before initiating treatment), myocardial infarction (within 6 months before initiating treatment), unstable angina, congestive heart failure (new york heart association class ≥grade ii) , serious arrhythmia which needs medication during the study and may affect the study or can not be controlled by drugs * unhealed wounds, active peptic ulcer or fracture * gastrointestinal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months before enrollment * women with intact uterus (menopause more than two years excluded) who are unwilling to take effective non-hormonal contraception (iud, spermicide barrier birth control device or sterilization) during the study. male who are unwilling to take effective contraceptive measures during the study * participated in other clinical trials within 28 days before the initiation of treatment. * allergic to any of the study drugs
safety and efficacy of iqp-lh-101 in postprandial heartburn

Conditions: Postprandial Heartburn

Summary: this study is a randomized, placebo-controlled, single-blind, three-way crossover clinical trial to evaluate safety and efficacy of iqp-lh-101 (tablet form and liquid form) in postprandial heartburn. the null hypothesis is that there is no difference between iqp-lh-101 and the placebo in terms of efficacy for postprandial heartburn treatment.


Eligibility criteria:
inclusion criteria: * post-prandial heartburn (e.g. after a high-fat meal) in at least 2 months prior to the study (at least 2 times a week) * not receiving prescribed treatment for heartburn, reflux or upper gastrointestinal disorders * written informed consent is a prerequisite for subject enrollment. exclusion criteria: * gastrointestinal bleeding within 12 months prior to the study * difficulty swallowing (dysphagia) * history of or symptoms suggestive of zollinger-ellison syndrome, oesophageal or gastric malignancy, gastric or duodenal ulcer, pernicious anaemia, barrett's oesophagus or systemic sclerosis * participation in other studies within the last 30 days prior to entry or during the study
sciatic block in contralateral limb phantom and residual limb pain

Conditions: Pain; Amputation

Summary: participants with chronic, refractory phantom limb pain (plp) or residual limb pain (rlp) for more than 6 months will be enrolled in this clinical trial. aim: define the attributable pain relief and functional improvement in participants with plp/rlp after contralateral limb sciatic nerve block. also, contribute to the basic science understanding of the crossed-withdraw reflex by demonstrating a known animal model phenomenon in human participants. hypothesis: contralateral limb sciatic nerve anesthetic block with 2% lidocaine provides immediate clinically meaningful pain reduction, defined as the proportion of patients with at least 50% improvement in numeric rating scale (nrs) pain score in plp/rlp when compared to sham.


Eligibility criteria:
inclusion criteria: * 1. age greater than 18 years of age at day of enrollment * 2. lower extremity amputation performed more than 12 months before study enrollment * 3. plp/rlp in affected amputated limb \> 4 on numeric rating scale 26 (nrs26) * 4. pain duration of more than 6 months despite a trial of conservative therapies for at least 2 months, including oral medications, topical medicines, physical therapy, and physical modalities (i.e., heat, cold, transcutaneous electrical nerve stimulation, phonophoresis) * 5. willingness to undergo image guided diagnostic nerve block exclusion criteria: * 1. refusal / inability to participate or provide consent * 2. contraindications to diagnostic nerve block * 3. non-neurogenic source of plp/rlp * 4. current opioid use \> 50 morphine milligram equivalents per day * 5. any interventional pain treatment in the residual limb within the last 30 days * 6. severe uncontrolled medical condition (i.e., hypertensive crisis, decompensated hypothyroidism) * 7. use of investigational pain drug within past 30 days or other concurrent clinical trial enrollment

Keywords: pain amputation phantom pain
position sense, force control and pain intensity in basal thumb osteoarthritis

Conditions: Thumb Osteoarthritis; Proprioceptive Disorders; Pain, Chronic

Summary: in practice, a single test is used to quantify thumb proprioception. previous studies have found a decrease in joint position sense (jps) and force sense (fs) in patients diagnosis of thumb carpometacarpal osteoarthritis, but no correlation have been stabilize between jps, fs and pain intensity perceived by the patient during activity daily life (adl). the goal of the study is compared joint position error (jpe) with joint force sense error (jfse) in subjects with carpometacarpal (cmc) joint osteoarthritis and investigated a possible correlation between thumb pain intensity and thumb proprioception in patients with cmc joint oa.

forty-five subjects over 18 with thumb cmc joint oa in the dominant hand grade 1-3 according o the eaton classification stage will be evaluated for thumb active joint position sense (jps) test and force sense test to measure proprioception function. for measurement of jps, the subjects will blindfolded and repositioned their thumb to a target position, which will be determined by the examiner previously. for force sense, participants will should reproduce pinch force measure with dynamometer. the severity of pain with activity will be measured according to the visual analog scale (vas).

Eligibility criteria:
inclusion criteria: * over 18 years; diagnosis of grade i, ii or ii thumb cmc joint oa in their dominant hand according to the eaton classification stage; a minimum pain rating of 4/10 on the visual analogue scale (vas) during activities of daily living (adls) at the time of the initial evaluation; ability to read and understand the patient information sheets and exercises exclusion criteria: * neurological disorder affecting the upper limb; treatment for hand or thumb pain in the same limb in the last 6 months (including injections to the wrist, fingers, or thumb); fracture or significant hand injury; previous surgery to the wrist or hand; hand/finger tenosynovitis; dupuytren disease; cognitive impairment that inhibited an understanding of the informed consent and exercise program; fixed thumb adduction contracture or blindness.
the potential therapeutic role of hydroxyethyl starch and hydrocortisone in acute aluminum phosphide poisoning

Conditions: Potential Therapeutic Role

Summary: aluminum phosphide (alp) is a widely used fumigant due to its efficiency as pesticides. it is available as tablets of celphos, alphos or quickphos which are known as rice tablets. each tablet weights 3 grams and contains 56% alp and 44% of aluminum carbonate and paraffin. the incidence of alp poisoning increased steadily specially in developing countries . alp poisoning is considered to be one of the major causes of suicidal poisoning owing to its wide accessibility and low cost. however, accidental poisoning may occur during occupational exposure

aluminum phosphide (alp) is a widely used fumigant due to its efficiency as pesticides. it is available as tablets of celphos, alphos or quickphos which are known as rice tablets. each tablet weights 3 grams and contains 56% alp and 44% of aluminum carbonate and paraffin. the incidence of alp poisoning increased steadily specially in developing countries . alp poisoning is considered to be one of the major causes of suicidal poisoning owing to its wide accessibility and low cost. however, accidental poisoning may occur during occupational exposure. signs and symptoms of acute alp poisoning include gastrointestinal, cardiovascular, hepatic, renal, and neurologic (1). ingestion of alp causes mild gastrointestinal (git) manifestations as nausea, vomiting, abdominal pain, in addition to chest tightness, hypotension, headache and dizziness. in severe cases, git hemorrhage, shock, severe metabolic acidosis, cardiac arrhythmia, convulsions and coma may occur. later, signs of hepatic damage and renal insufficiency may develop. death usually occurs in 30-70% of cases within the first 24 hours resulting from refractory cardiogenic shock, cardiac arrhythmia, severe hypotension and metabolic acidosis.the main causes of cardiovascular collapse are increase capillary permeability, insufficient systemic vasoconstriction with low ventricular ejection fraction. on autopsy examinations, point to extravasation of fluid into the third space. the management is exclusively supportive as gastric lavage with kmno4 solution, treatment of hypotension and acidosis in view of the fact that there is no specific antidote available.

Eligibility criteria:
inclusion criteria: * patients with severe acute aluminum phosphide poisoning * systolic blood pressure (sbp) ≤90 mmhg * ph ≤ 7.2 * hco3 ≤15 meq/l * during the first six hours of admission exclusion criteria: * pregnant and lactating women * asymptomatic patients with history of acute aluminum phosphide exposure. * patients with co-ingestion to other substances in addition to aluminum phosphide. * patients with other major medical conditions (e.g. cardiovascular disease, renal or hepatic failure). * patients with previous medical intervention (fluid therapy and vasopressors).
study to evaluate the safety and efficacy of ctp-656 in patients with cystic fibrosis with cftr gating mutations

Conditions: Cystic Fibrosis

Summary: this study will evaluate the efficacy and safety of ctp-656 in patients with cystic fibrosis (cf) who have a cystic fibrosis transmembrane conductance regulator (cftr) gating mutation.

this is a randomized, parallel-group, double-blind, placebo controlled multicenter study to evaluate the safety and efficacy of ctp-656 in cf patients with cftr gating mutations, compared to kalydeco, for a total of 28 days. subjects will be randomized to receive either double-blind ctp-656 or placebo, or open-label kalydeco.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * has a confirmed diagnosis of cf with at least one allele of the following cftr gating mutations: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n, and s549r. * has been stable on kalydeco therapy for at least 3 months prior to screening * has fev1 ≥ 60% of predicted normal for age, sex, and height at screening and baseline (day 1) assessments * weighs at least 40 kg at screening * patients of either gender and women of childbearing potential must be willing to use a medically highly effective form of birth control during the treatment period and 30 days after the last dose of study treatment. exclusion criteria: * acute upper respiratory infection or lower respiratory infection, pulmonary exacerbation, or changes in therapy within 4 weeks of study treatment * uncontrolled type 2 diabetes, or uncontrolled cf-related diabetes * history of hepatitis c or chronic active hepatitis b infection * history of pulmonary tuberculosis, non-tuberculosis mycobacterial infections or allergic bronchopulmonary aspergillosis (abpa) treated during screening or within 2 years prior to screening * colonization with b. cenocepacia, b. dolosa, b. multivorans, and/or m. abcessus within 2 years prior to screening * abnormal liver function * history of abnormal renal function * history of prolonged qtcf \> 450 msec for males or qtcf \> 470 msec for females * history of solid organ or hematological transplantation * using any inhibitor or inducer of cytochrome p450/3a during the study or within 30 days of screening * women who are pregnant or lactating, or have plans to become pregnant during the study or within 1 month following the last dose
emergency stroke unit for acute cerebrovascular events ( esu-ace-a )

Conditions: Ischemic Stroke, Acute

Summary: to compare the door-to-needle time of patients with hyperacute ischemic stroke (within 4.5 hours after the onset of symptoms) managed in a standard stroke unit adherent to guidelines versus managed in emergency stroke unit (a new stroke unit based on low-field magnetic resonance imaging).

intravenous thrombolysis is an effective reperfusion therapy for patients with acute ischemic stroke. faster door-to-needle time (dnt) is associated with significantly better clinical outcomes. with the development of low-field magnetic resonance imaging, it is poised to play an increasingly significant role in the early diagnosis and management of acute ischemic stroke. this prospective, multicenter, week-wise randomized controlled trial will compare the door-to-needle time of patients with hyperacute ischemic stroke (within 4.5 hours after the onset of symptoms) managed in a standard stroke unit adherent to guidelines versus managed in emergency stroke unit (a new stroke unit based on low-field magnetic resonance imaging).

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; 2. can be treated within 4.5 hours of symptoms onset\*(\*symptom onset is defined by the "last seen normal" principle); 3. presenting with ischemic stroke symptoms; 4. pre-stroke mrs score 0-1; 5. baseline nihss score ≥ 5; 6. eligible for rt-pa/tnk thrombolysis; 7. informed consent signed. exclusion criteria: 1. baseline nihss score \< 5; 2. unable to undergo mri because of claustrophobia; 3. patients with cardiac pacemaker/brain pacemaker/insulin pump implantation; 4. definite contraindication for rt-pa/tnk thrombolysis; 5. patients with postictal hemiparesis (todd's paralysis) or those with concomitant neurological/psychiatric conditions who are unable or unwilling to cooperate; 6. pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of trial; 7. participation in other interventional randomized clinical trials within 3 months before enrollment; 8. patients deemed unsuitable for participation in this trial by the investigator or those for whom participation in this trial may result in greater risks.

Keywords: emergency stroke unit low-field magnetic resonance imaging reperfusion therapy intravenous thrombolysis